The company, a unit of French drug maker Sanofi-Aventis, said total sales slid 9.2% on the year to RON235.6 million.
Zentiva posted total revenue of RON255.8 million in 2011, down 5.1% on the year, while overall costs rose 6.4% to RON231.7 million.
The company has a share capital of RON41.6 million split into 416.9 million shares with a face value of RON0.1.
French group Sanofi-Aventis owns 78.3% in Zentiva Romania.
At around 14:00 Thursday, Zentiva’s shares traded down 5.54% at RON0.92 in Bucharest. (EUR1=RON4.3497)